Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

In this study (n=3092), once-daily combination of mometasone, indacaterol and glycopyrronium (MF–IND–GLY) was associated with superior improvements in trough FEV1 vs corresponding doses of MF-IND at week 26 (treatment difference 76mL medium dose and 65mL high dose; both p<0.001).

SPS commentary:

Once-daily MF-IND-GLY was also associated with larger improvements in trough FEV1 when compared to high-dose fluticasone–salmeterol (500 μg, 50 μg; twice daily via Diskus), with improvements of 99mL (medium dose) and 119mL (high-dose) at 26 weeks (both p<0.001).


Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) was approved in the EU in July 2020 for the maintenance treatment of asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high-dose inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.


The Lancet Respiratory Medicine

Resource links: